Transparency reporting
Below is information containing Camurus' disclosures of transfers of values, which is made available in accordance with applicable laws, regulations and/or industry code. In addition, more detailed information regarding Camurus' grants and donations to healthcare and patient organizations, and Investigator Sponsored Studies are disclosed below.
Transfers of values to healthcare and/or patient organizations
Germany:
Camurus GmbH Veroeffentlichung der AKG Transparenzregel 2023 (Excel, German)
Camurus GmbH Transparency reporting AKG 2023 (Excel, English)
Camurus GmbH Veroeffentlichung der AKG Transparenzregel 2022 (Excel, German) Camurus GmbH Transparency reporting AKG 2022 (Excel, English)
Belgium: Transparency register – Be Transparent
France: Transparence – Santé Public
Grants and donations to healthcare and patient organizations
See below for information on grants and donations provided by Camurus AB since January 2022, including requests for such support which have been received by the company’s subsidiaries.
The disclosure includes grants and donations given to healthcare organizations (eg. healthcare, medical or scientific association or society, hospital, clinic, foundation, university or other teaching institution), or similar (e.g. research institutions in the field of medicine), and patient organizations and similar.
During 2025, the list below will be updated regularly, as new projects have been granted support by Camurus and are agreed with the recipient organization.
Previous years:
Grants and donations disclosure 2024 (pdf)
Grants disclosure 2023 (pdf)
Grants disclosure 2022 (pdf)
Grants disclosures and donations 2025
| Approval date | Organization (recipient) | Country/ region (recipient) | Patient organization | Grant project description | Purpose/category | Amount |
|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - |
Investigator Sponsored Studies (ISS)
Camurus has several Investigator Sponsored Studies (ISS) – research projects run by external researchers with support from Camurus ongoing, which aims to strengthen the scientific evidence base. Camurus assists in these studies with financial support and/or with product, but is not involved in the design, execution, or interpretation of the results.
Investigator Sponsored Study (ISS) disclosure
| ONGOING | ||||
|---|---|---|---|---|
| Approval date/ contract signing | Organization (recipient) | Country (recipient) | Title of ISS | Amount |
| 16 September 2024 | University of Dundee | UK | Long-acting Buprenorphine and influence on non-fatal overdose in Tayside | 168,880 GBP |
| 23 June 2023 | University of Bordeaux | France | OBAP-A prospective observational study in naturalistic settings to describe Buvidal introduction in France: change in severity of addiction and health related quality of life over a period of 3 months | 312,928.80 EUR |
| 13 December 2023 | LVR University Hospital Essen, University of Duisburg-Essen | Germany | Substitution im Alter - Substitution treatment in the elderly – Needs, fears and expectancies of an age-based treatment | 12,000 EUR |
| FINISHED | ||||
| Approval date/ contract signing | Organization (recipient) | Country (recipient) | Title of ISS | Amount |
| 11 January 2023 | Medical University Centre Hamburg-Eppendorf (UKE) | Germany | Evaluation of treatment needs among opioid dependent drug users currently not in opioid substitution treatment | 83,900 EUR |
| 14 June 2023 | Monash University | Australia | Australian clinicians’ views, knowledge and experiences of long-acting injectable buprenorphine: How can care be optimised in the future? | 99,983 EUR |